What is Kura Oncology's D&A?

Kura Oncology (KURA) reported D&A of $355K in Q1 2026.

How has Kura Oncology's D&A changed year-over-year?

Kura Oncology's D&A increased by 47.3% year-over-year, from $241K to $355K.

What is the long-term trend for Kura Oncology's D&A?

Over 4 years (2021 to 2025), Kura Oncology's D&A has grown at a 16.6% compound annual growth rate (CAGR), from $558K to $1.03M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Kura Oncology KURA D&A

D&A at other companies

Johnson & JohnsonJNJ

$2B+13.1%

AmgenAMGN

$1.12B-19.5%

ExelixisEXEL

$6.95M-5.4%

Corvus PharmaceuticalsCRVS

$29K+31.8%

Nuvation BioNUVB

$536K+72.9%

Arcus BiosciencesRCUS

$2M-33.3%

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's D&A?: Kura Oncology (KURA) reported D&A of $355K in Q1 2026.
How has Kura Oncology's D&A changed year-over-year?: Kura Oncology's D&A increased by 47.3% year-over-year, from $241K to $355K.
What is the long-term trend for Kura Oncology's D&A?: Over 4 years (2021 to 2025), Kura Oncology's D&A has grown at a 16.6% compound annual growth rate (CAGR), from $558K to $1.03M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.